Many active pharmaceutical ingredients used in compounded drugs are imported from overseas facilities, which must be inspected and registered by the FDA
67% Improvement in baseline metabolic flexibility scores during first 60 days of treatment
It gets the name seed-under-leaf because its seed pods, which bloom into small green flowers, grow beneath the leaves
Important caveat: the idea that a GHRH analog plus a ghrelin agonist produce additive or synergistic GH output is a reasonable hypothesis, but it has not been validated for this specific blend or its dosing
The results were consistent: Trunk fat reduction: Tesamorelin-treated patients showed statistically significant reductions in trunk fat versus placebo at 26 weeks.[1] VAT reduction: Using cross-sectional CT imaging, tesamorelin produced approximately 1520% reductions in visceral adipose tissue compared to placebo.[1,2] Triglyceride improvement: Alongside fat reduction, tesamorelin improved triglyceride levels a key marker in metabolic syndrome.[2] Tesamorelin IGF-1 elevation: Treatment reliably elevated IGF-1 levels toward age-appropriate norms, confirming successful GH-axis stimulation.[1] These reductions occurred without dietary caloric restriction being mandated